普瑞巴林辅助抗组胺类药物治疗尿毒症行维持性血液透析患者继发皮肤瘙痒的临床观察
x

请在关注微信后,向客服人员索取文件

篇名: 普瑞巴林辅助抗组胺类药物治疗尿毒症行维持性血液透析患者继发皮肤瘙痒的临床观察
TITLE:
摘要: 目的:观察普瑞巴林辅助抗组胺类药物治疗尿毒症行维持性血液透析患者继发皮肤瘙痒的临床疗效及安全性。方法:140例尿毒症行维持性血液透析继发皮肤瘙痒的患者,根据抽签法分为对照组和治疗组,各70例。对照组患者单用氯雷他定10 mg,qd,po;治疗组患者在对照组基础上加用普瑞巴林辅助治疗,于透析结束当晚口服75 mg,如未见明显缓解可每周加量75 mg,最大剂量为300 mg。两组患者均治疗3个月。比较两组患者临床疗效和治疗前后瘙痒VAG评分、改良Duo氏瘙痒评分、匹兹堡睡眠质量指数(PSQI)评分及不良反应发生率。结果:治疗组患者临床总有效率(90.00%)明显高于对照组(71.43%),差异有统计学意义(P<0.05);治疗组患者治疗后瘙痒VAG评分、改良Duo氏瘙痒评分和PSQI评分均明显低于对照组及治疗前,差异有统计学意义(P<0.05);两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论:普瑞巴林辅助抗组胺类药物治疗尿毒症行维持性血液透析患者继发皮肤瘙痒可有效缓解瘙痒症状、提高患者睡眠质量,且不增加不良反应发生风险。
ABSTRACT: OBJECTIVE: To observe the clinical efficacy and safety of pregabalin assisting anti-histamine drugs in the treatment of secondary skin pruritus in uremic patients underwent maintenance hemodialysis. METHODS: 140 uremic patients with secondary skin pruritus underwent maintenance hemodialysis were randomly divided into control group and treatment group, with 70 cases in each group. Control group was given loratadine orally, 10 mg, qd. Treatment group was additionally given pregabalin on the basis of control group, 75 mg, po, at night of hemodialysis end, increasing by 75 mg every week if no obvious relief was found, maximal dose of 300 mg. Both group received 3 months of treatment. Clinical efficacy, VAG itching score, modified Duo score, PSQI score before and after treatment and the incidence of ADR were compared between 2 groups. RESULTS: Total effective rate of treatment group (90.00%) was significantly higher than that of control group (71.43%), with statistical significance (P<0.05); VAG itching score, modified Duo score and PSQI score of treatment group after treatment were significantly lower than control group and before treatment, with statistical significance (P<0.05). There was no significant difference in the incidence of ADR between 2 groups(P>0.05). CONCLUSIONS: Pregabalin assisting anti-histamine drugs in the treatment of secondary skin pruritus in uremic patients with maintenance hemodialysis can efficiently relieve the itching symptoms, improve sleep quality, and not increase the risk of ADR.
期刊: 2016年第27卷第5期
作者: 鲁娟,周小栋,谭伟
AUTHORS: LU Juan,ZHOU Xiaodong,TAN Wei
关键字: 普瑞巴林;抗组胺类药物;尿毒症;维持性血液透析;皮肤瘙痒
KEYWORDS: Pregabalin; Anti-histamine drugs; Uremia; Maintenance hemodialysis; Skin pruritus
阅读数: 592 次
本月下载数: 3 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!